Lineage Cell Therapeutics Inc. — Director's Dealing 2016

Jul 6, 2016

FORM 4
-----------	--

[ ] Check this box if no longer subject to Section 16. Form 4 or continue. See Instruction 1(b).

FORM 4 Washington, D.C. 20549

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Form 5 obligations may UNITED STATES SECURITIES AND EXCHANGE COMMISSION STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES OMB APPROVAL

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer
		(Check all applicable)
SCHLACHET DAVID	BIOTIME INC [ BTX ]
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	__ X __ Director _____ 10% Owner
		_ Officer (give title below) ___ Other (specify below)
1010 ATLANTIC AVENUE, SUITE 102	7/1/2016
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		(Instr. 3, 4 and 5)	4. Securities Acquired (A) or Disposed of (D)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form:	7. Nature of Indirect Beneficial
			Code	V	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Shares, no par value								32050	I	see footnote (1)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned	10. Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)
Option to Purchase Common Shares	\$2.72	7/1/2016		A		20000		(2)	6/30/2021	Common Shares	20000	\$0.00	20000	D
Option to Purchase Common Shares	\$3.57							(3)	6/30/2020	Common Shares	20000		20000	D
Option to Purchase Common Shares	\$3.11							(4)	6/30/2019	Common Shares	20000		20000	D
Option to Purchase Common Shares	\$2.86							(5)	4/10/2019	Common Shares	20000		20000	D

Explanation of Responses:

( 1) All shares are owned by Schlachet Management Ltd., a privately held company of which Mr. Schlachet is the sole shareholder, chief executive officer, and director.

( 2) Will become exercisable in four equal quarterly installments based upon continued service on the board of directors.

( 3) Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015.

( 4) Became exercisable in four equal quarterly installments after the date of grant on July 1, 2014.

( 5) Became exercisable in four equal quarterly installments after the date of grant on April 11, 2014.

Reporting Owners

		Relationships
Reporting Owner Name / Address	Director	10% OwnerOfficerOther
SCHLACHET DAVID

	1010 ATLANTIC AVENUE SUITE 102 ALAMEDA, CA 94501	X
--	--------------------------------------------------------	---	--	--	--	--	--	--	--

Signatures

/s/David Schlachet 7/5/2016
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.